Epidemiological Study in Thai Participants With Hypertension

Takeda2,071 enrolled

Overview

The purpose of this study is to evaluate blood pressure (BP) goal attainment in adult participants with essential hypertension.

This study has been designed as a non-interventional, observational study to obtain information on hypertension treatment regimens and how well hypertension is controlled in Thai patients in real-life settings. Antihypertensive medications prescribed in this study will be at the discretion of the investigator and the standard of care practice at the particular study site. The study will enroll approximately 2000 patients. Participants with well-controlled hypertension on their current antihypertensive therapy will participate in the study for only 1 visit. Participants with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks. These participants will make 3 visits to the study site. This multi-centre trial will be conducted in Thailand.

Study Type

OBSERVATIONAL

Enrollment

2,071

Conditions

Hypertension

Interventions

No InterventionOTHER

No intervention was administered in this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ability to provide written informed consent 2. Age above 18 years. 3. Participants with essential hypertension as per European Society of Hypertension/European Society of Cardiology (ESH/ESC) criteria in general, target blood pressure (BP), systolic blood pressure (SBP) \<140 and diastolic blood pressure (DBP) \<90 mmHg, in diabetes, target BP, SBP \<140 and DBP \<85 mmHg, in renal disease with overt proteinuria (urine albumin excretion \> 300 mg/day or 200 microgram/min), target BP, SBP \<130 and DBP \<90 mmHg). Essential Hypertension will be defined based on the criteria established by the ESH/ESC 2013 criteria: * Grade 1 Essential hypertension - Systolic blood pressure (SBP) 140 - 159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg with no identifiable cause * Grade 2 Essential hypertension - SBP 160 - 179 mmHg and/or DBP 100 - 109 mmHg with no identifiable cause * Grade 3 Essential hypertension-SBP ≥ 180 and/or DBP ≥ 110 mmHg with no identifiable cause. Exclusion Criteria: 1. Female participants who are breastfeeding or pregnant or who are intending to become pregnant. 2. Has known or suspected secondary hypertension. 3. Is currently enrolled in or has not yet completed at least 30 days since ending an investigational product or device study or is receiving other investigational agents.

Locations (1)

Unnamed facility

Pathumwan, Bangkok, Thailand

Outcomes

Primary Outcomes

Percentage of Participants with Controlled Treated Hypertension

Time frame: Up to 16 weeks

Secondary Outcomes

Percentage of Participants for Whom Dose of Current Medications was Increased

Time frame: Up to 16 weeks

Percentage of Participants for Whom Antihypertensive Medications were Switched

Time frame: Up to 16 weeks

Percentage of Participants for Whom Second Antihypertensive Drug was Added

Time frame: Up to 16 weeks

Percentage of Participants for Whom One or More of the Compound of Index Treatment was Removed

Time frame: Up to 16 weeks

Percentage of Participants in Whom There was No Change in Treatment Regimen

Time frame: Up to 16 weeks

Reason for Choosing the Treatment Regimens in Hypertension Treatment

Time frame: Up to 16 weeks

Treatment Regimen for Hypertension

Treatment regimen for hypertension will be either monotherapy or combination therapy.

Time frame: Up to 16 weeks

Types of Antihypertensive Medications and Medication Classes

Time frame: Up to 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.